Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

116.82USD
20 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$116.82
Open
$114.06
Day's High
$118.99
Day's Low
$113.16
Volume
577,927
Avg. Vol
553,207
52-wk High
$140.76
52-wk Low
$102.21

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 61.23 31.23 33.59
EPS (TTM): 2.31 -- --
ROI: 4.17 15.57 15.05
ROE: 6.11 16.94 16.62

US STOCKS-Wall Street rally disintegrates shortly before the close

* Indexes: Dow Jones -0.40 pct, S&P 500 -0.33 pct, Nasdaq -0.21 pct (Adds investor comment, details on stock moves)

26 Sep 2018

US STOCKS-Health stocks lift Wall St as banks dip ahead of expected rate hike

* Indexes up: 0.22 pct, S&P 0.25 pct, Nasdaq 0.34 pct (Changes comment, updates prices, adds details)

26 Sep 2018

US STOCKS-Health shares prop up Wall St as banks dip ahead of expected rate hike

* Indexes: 0.15 pct, S&P 0.15 pct, Nasdaq 0.22 pct (Updates to open)

26 Sep 2018

Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

26 Sep 2018

UPDATE 1-Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

26 Sep 2018

Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.

26 Sep 2018

Earnings vs. Estimates